Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2018-04-11 Board/Management Inform…
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Verona Pharma Announces Departure of Chief Medical Officer
Board/Management Information Classification · 1% confidence The document is a press release dated April 11, 2018, announcing that Dr. Kenneth Newman has resigned as Chief Medical Officer, effective April 30, 2018. This constitutes an announcement of a change in senior management. This directly matches the definition for Board/Management Information (MANG). Although it mentions the Form 20-F filing, the primary content is the management change announcement, not the filing itself.
2018-04-11 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1162 characters) and its primary content is an announcement regarding a 'Price Monitoring Extension' for a security, referencing an 'RNS Number' and stating that this information is provided by 'RNS, The company news service from the London Stock Exchange'. This structure strongly suggests a general regulatory announcement that doesn't fit specific financial reporting categories like 10-K, ER, or IR. Since it is a general regulatory notice provided via the RNS system and doesn't fit the definitions for AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS, the most appropriate fallback category is Regulatory Filings (RNS).
2018-04-09 English
Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD
Earnings Release Classification · 1% confidence The document is a press release announcing positive top-line data from a Phase 2b clinical trial for a drug candidate (RPL554) for COPD. It includes key efficacy and safety results, quotes from management and investigators, and details about an upcoming conference call to discuss the results. This format—a formal announcement of preliminary or key results, often preceding a full report or filing—is characteristic of an Earnings Release (ER) or a general press announcement. Since it is focused on announcing financial/clinical results (positive data) and includes a call to discuss these results, it aligns best with the 'Earnings Release' definition, which covers the initial announcement of periodical financial/operational results. Although it is clinical data, in the context of a clinical-stage biopharma company, the release of 'top-line data' functions as the primary periodic operational update, similar to an earnings release for other sectors. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or just a simple announcement of a report publication (RPA). Q1 2018
2018-03-26 English
Research Collaboration with Imperial College
Legal Proceedings Report Classification · 1% confidence The document is identified by the 'RNS Number : 2047I' header and concludes with 'This information is provided by RNS The company news service from the London Stock Exchange END'. This strongly indicates a regulatory news service announcement. The content describes a new research collaboration and provides updates on product development (SFX-01), which is typical for general corporate news released via an RNS feed. Since it is not a specific financial report (like 10-K, IR, ER) or a specific corporate action announcement (like DIV, CAP, DIRS), and it is a general regulatory announcement, the most appropriate classification is Regulatory Filings (RNS). The document length (4776 chars) is moderate, but the explicit RNS branding overrides the 'Menu vs Meal' rule which typically applies to short announcements linking to a full report.
2018-03-20 English
Verona Pharma to Present at Upcoming Healthcare Investor Conferences
Report Publication Announcement Classification · 1% confidence The document is a press release from Verona Pharma plc announcing that company management will present at three upcoming investor conferences (Oppenheimer, Needham, and H.C. Wainwright) in March and April 2018. It details the event names, dates, times, and locations. This type of announcement, which informs investors about management's schedule for meeting with analysts and investors at industry events, is best classified as an Investor Presentation (IP) announcement or related material, although the document itself is an announcement *about* future presentations rather than the presentation slides themselves. Given the options, 'Investor Presentation' (IP) is the closest fit as it relates directly to management engaging with investors at conferences. However, since the document is purely an announcement of the schedule and not the presentation material itself, and it doesn't fit the strict definition of an Earnings Release (ER) or a formal regulatory filing, it could also be considered a general Regulatory Filing (RNS) or potentially a type of Investor Relations communication. Since the core purpose is to inform investors about management's upcoming engagement schedule, 'Investor Presentation' (IP) is the most contextually relevant category for investor-facing schedule updates, even if it's not the presentation deck itself. Given the short length and announcement nature, RPA or RNS are alternatives, but IP captures the subject matter best.
2018-03-15 English
Verona Pharma plc: 2017 Annual Report and Accounts and Notice of AGM
Report Publication Announcement Classification · 1% confidence The document explicitly states that the hard copy of the 'Annual Report and Accounts for the year ended 31 December 2017' and the 'Notice of Annual General Meeting' have been posted to shareholders. It also confirms the date and location of the upcoming Annual General Meeting (AGM). Since the document's primary function is to announce the availability and posting of the Annual Report and the AGM details, and given its short length (3084 chars), it fits the definition of a Report Publication Announcement (RPA) rather than the full Annual Report (10-K) or AGM materials (AGM-R) themselves. It is announcing the publication of those documents.
2018-03-09 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.